U.S., April 11 -- ClinicalTrials.gov registry received information related to the study (NCT06921850) titled 'A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa' on April 03.
Brief Summary: The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
Study Start Date: April 30
Study Type: INTERVENTIONAL
Condition:
Hidradenitis Suppurativa
Intervention:
DRUG: Bimekizumab
Bimekizumab will be administered at pre-specified timepoints.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: UCB Biopharma SRL
Published by HT Digital Conte...